P53siRNA therapy reduces cell proliferation, migration and induces apoptosis in triple negative breast cancer cells

Molecular and Cellular Biochemistry

Volumn 381, Issue 1-2, 2013, Pages 61-68

  Braicu, Cornelia ^a,b   Pileczki, Valentina ^a   Irimie, Alexandru ^a,b   Berindan Neagoe, Ioana ^a,b  

^a IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^b THE ONCOLOGY INSTITUTE PROF DR ION CHIRICUTA   (Romania)

Author keywords

Apoptosis; Cell proliferation; Migration; P53siRNA; Triple negative breast cells

Indexed keywords

PROTEIN BCL 2; PROTEIN P53; SMALL INTERFERING RNA;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CELL GROWTH; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; GENE EXPRESSION; GENE THERAPY; HUMAN; HUMAN CELL; RNA INTERFERENCE; TRIPLE NEGATIVE BREAST CANCER;

EID: 84882639080     PISSN: 03008177     EISSN: 15734919     Source Type: Journal    
DOI: 10.1007/s11010-013-1688-5     Document Type: Article

References (32)

1. Wang Z, Sun Y (2010) Targeting p53 for novel anticancer therapy. Transl Oncol 3(1):1-12
2. Finlay CA, Hinds PW, Levine AJ (1989) The p53 proto-oncogene can act as a suppressor of transformation. Cell 57(7):1083-1093
3. Bishayee A, Ahmed S, Brankov N, Perloff M (2011) Triterpe-noids as potential agents for the chemoprevention and therapy of breast cancer. Front Biosci 16:980-996
4. Rahman M, Davis SR, Pumphrey JG, Bao J, Nau MM, Meltzer PS, Lipkowitz S (2009) TRAIL induces apoptosis in triple-negative breast cancer cells with a mesenchymal phenotype. Breast Cancer Res Treat 113(2):217-230
5. Liu Y-Y, Patwardhan G, Bhinge K, Gupta V, Gu X, Jazwinski M (2011) Suppression of glucosylceramide synthase restores p53-dependent apoptosis in mutant p53 cancer cells. Cancer Res 71(6):2276-2285
6. Norberg T, Klaar S, Karf G, Nordgren H, Holmberg L, Bergh J (2001) Increased p53 mutation frequency during tumor progres-sion-results from a breast cancer cohort. Cancer Res 61:8317-8321
7. Sigal A, Rotter V (2000) Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome. Cancer Res 60:6788-6793
8. Vikhanskaya F, Lee K, Mazzoletti M, Broggini M, Sabapathy K (2007) Cancer-derived p53 mutants suppress p53-target gene expression-potential mechanism for gain of function of mutant p53. Nucleic Acids Res 35(6):2093-2104
9. Kim DH, Rossi JJ (2007) Strategies for silencing human disease using RNA interference. Nat Rev Genet 8:173-184
10. Brummelkamp TR, Bernards R, Agami R (2002) Stable suppression of tumorigenicity by virus-mediated RNA interference. Cancer Cell 2:243-247
11. Kim DH, Rossi JJ (2007) Strategies for silencing human disease using RNA interference. Nat Rev Genet 8:173-184
12. Rye PD, Stigbrand T (2004) Interfering with cancer: A brief outline of advances in RNA interference in oncology. Tumor Biology 25:5-6
13. Lacroix M, Toillon RA, Leclercq G (2006) p53 and breast cancer, an update. Endocr Relat Cancer 13(2):293-325
14. Gasco M, Shami S, Crook T (2002) The p53 pathway in breast cancer. Breast Cancer Res 4:70-76
15. Ma CX, Cai S, Li S, Ryan CE, Guo Z, Schaiff WT, Lin L, Hoog J, Goiffon RJ, Prat A, Aft RL, Ellis MJ, Piwnica-Worms H (2012) Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor Models. J Clin Invest 122(4):1541-1552
16. Zhao R, Gish K, Murphy M, Yin Y, Notterman D, Hoffman WH, Tom E, Mack DH, Levine AJ (2000) Analysis of p53-regulated gene expression patterns using oligonucleotide arrays. Genes Dev 14:981-993
17. Zhou M, Liu Z, Zhao Y, Ding Y, Liu H, Xi Y, Xiong W, Li G, Lu J, Fodstad O, Riker AI, Tan M (2010) MicroRNA-125b confers the resistance of breast cancer cells to paclitaxel through suppression of pro-apoptotic Bcl-2 antagonist killer 1 (Bak1) expression. J Biol Chem 285(28):21496-21507
18. Scott GB, Bowles PA, Wilson EB, Meade JL, Low BC, Davison A, Davison A, Blair GE, Cook GP (2010) Identification of the BCL2/adenovirus E1B-19K protein-interacting protein 2 (BNIP-2) as a granzyme B target during human natural killer cellmediated killing. Biochem J 431:423-431
19. Morel C, Carlson SM, White FM, Davis RJ (2009) Mcl-1 integrates the opposing actions of signaling pathways that mediate survival and apoptosis. Mol Cell Biol 29(14):3845-3852
20. Plati J, Bucur O, Khosravi-Far R (2011) Apoptotic cell signaling in cancer progression and therapy. Integr Biol (Camb) 3(4):279-296
21. Bruey JM, Bruey-Sedano N, Luciano F, Zhai D, Balpai R, Xu C, Kress CL, Bailly-Maitre B, Li X, Osterman A, Mastsuzawa S, Terskikh AV, Faustin B, Reed JC (2007) Bcl-2 and Bcl-XL regulate proinflammatory caspase-1 activation by interaction with NALP1. Cell 129:45-56
22. Aggarwal BB, Shishodia S, Sandur SK, Pandey MK, Sethi G (2006) Inflammation and cancer: how hot is the link? Biochem Pharmacol 72(11):1605-1621
23. Elmore S (2007) Apoptosis: a review of programmed cell death. Toxicol Pathol 35(4):495-516
24. Booy EP, Henson ES, Gibson SB (2011) Epidermal growth factor regulates Mcl-1 expression through the MAPK-Elk-1 signalling pathway contributing to cell survival in breast cancer. Oncog 30:2367-2378
25. Woods NT, Yamaguchi H, Lee FY, Bhalla KN (2007) Wang Anoikis HG. initiated by Mcl-1 degradation and Bim induction, is deregulated during oncogenesis. Cancer Res 67:10744
26. Qin W, Hu J, Guo M, Xu J, Li J, Yao G et al (2003) BNIPL-2, a novel homologue of BNIP-2, interacts with Bcl-2 and Cdc42GAP in apoptosis. Biochem Biophys Res Commun 308:379-385
27. Debily MA, Marhomy SE, Boulanger V, Eveno E, Mariage-Samson R, Camarca A et al (2009) A functional and regulatory network associated with PIP expression in human breast cancer. PLoS One 4(3):4696
28. Lu Y, Chen GQ (2011) Effector caspases and leukemia. Int J of Cell Biol. doi:10.1155/2011/738301
29. Valentín-Acevedo A, Sinquett FL, Covey LR (2011) c-Rel deficiency increases caspase-4 expression and leads to ER stress and necrosis in EBV-transformed cells. PLoS One 6(10):25467
30. Smolnikar K, Löffek S, Schulz T, Michna H, Diel P (2000) Treatment with the pure antiestrogen faslodex (ICI 182780) induces tumor necrosis factor receptor 1 (TNFR1) expression in MCF-7 breast cancer cells. Breast Cancer Res Treat 63(3):249-259
31. Adams JM, Cory S (2007) The Bcl-2 apoptotic switch in cancer development and therapy Bcl-2 apoptotic switch in cancer. Oncog 26:1324-1337
32. Miller LD, Smeds J, George J, Vega VB, Vergara L, Ploner A (2005) An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. PNAS 2(38):13550-13555